Compare Amphastar Pharmaceuticals Inc (AMPH) vs United States Natural Gas Fund (UNG) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

UNG (United States Natural Gas Fund) trades at $10.60, down 2.12% amid bearish technical signals with 17 sell indicators versus 3 buy signals. The ETF faces headwinds from natural gas price volatility, though RSI levels near 30 suggest potential oversold conditions. Recent news highlights weather-driven demand fluctuations and structural challenges including contango effects that have historically eroded long-term returns.

Outlook remains cautious given the fund's tracking of futures contracts rather than company fundamentals. Key risks include weather dependency and LNG export volatility, while oversold technical conditions may offer short-term trading opportunities for risk-tolerant investors.